Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neurotox Res. 2013 Apr;23(3):225-37. doi: 10.1007/s12640-012-9338-3. Epub 2012 Jul 7.
Two important pathophysiological mechanisms involved during cerebral ischemia are oxidative stress and inflammation. In pathological conditions such as brain ischemia the ability of free radicals production is greater than that of elimination by endogenous antioxidative systems, so brain is highly injured due to oxidation and neuroinflammation. Fibrates as peroxisome proliferator-activated receptor (PPAR)-α ligands, are reported to have antioxidant and anti-inflammatory actions. In this study, gemfibrozil, a fibrate is investigated for its therapeutic potential against global cerebral ischemia-reperfusion (I/R) injury of male and female rats. This study particularly has focused on inflammatory and antioxidant signaling pathways, such as nuclear factor erythroid-related factor (Nrf)-2, as well as the activity of some endogenous antioxidant agents. It was found that pretreatment of animals with gemfibrozil prior to I/R resulted in a sexually dimorphic outcome. Within females it proved to be protective, modulating inflammatory factors and inducing antioxidant defense system including superoxide dismutase (SOD), catalase, as well as glutathione level. However, Nrf-2 signaling pathway was not affected. It also decreased malondialdehyde level as an index of lipid peroxidation. In contrast, gemfibrozil pretreatment was toxic to males, enhancing the expression of inflammatory factors such as tumor necrosis factor-α, nuclear factor-κB, and cyclooxygenase-2, and decreasing Nrf-2 expression and SOD activity, leading to hippocampal neurodegeneration. Considering that gemfibrozil is a commonly used anti-hyperlipidemic agent in clinic, undoubtedly more investigations are crucial to exactly unravel its sex-dependent neuroprotective/neurodegenerative potential.
在脑缺血期间涉及两个重要的病理生理机制是氧化应激和炎症。在病理条件下,如脑缺血,自由基的产生能力大于内源性抗氧化系统的消除能力,因此由于氧化和神经炎症,大脑受到高度损伤。贝特类作为过氧化物酶体增殖物激活受体(PPAR)-α配体,据报道具有抗氧化和抗炎作用。在这项研究中,吉非罗齐,一种贝特类药物,被研究其对雄性和雌性大鼠全脑缺血再灌注(I / R)损伤的治疗潜力。本研究特别关注炎症和抗氧化信号通路,如核因子红细胞相关因子(Nrf)-2,以及一些内源性抗氧化剂的活性。结果发现,缺血再灌注前用吉非罗齐预处理动物会产生性别二态性结果。在女性中,它被证明是具有保护作用的,调节炎症因子,并诱导抗氧化防御系统,包括超氧化物歧化酶(SOD)、过氧化氢酶和谷胱甘肽水平。然而,Nrf-2 信号通路不受影响。它还降低了丙二醛水平作为脂质过氧化的指标。相比之下,吉非罗齐预处理对雄性有毒,增加了炎症因子的表达,如肿瘤坏死因子-α、核因子-κB 和环氧化酶-2,并降低了 Nrf-2 表达和 SOD 活性,导致海马神经退行性变。考虑到吉非罗齐是临床上常用的抗高血脂药物,毫无疑问,需要进行更多的研究来准确揭示其性别依赖性神经保护/神经退行性变的潜力。